

Portfolio Companies
TF Capital has invested in nearly 100 companies, including successful NASDAQ, HKG, ChiNext Board and STAR market IPOs.
Zai Lab Limited
(NASDAQ:ZLAB)
research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for oncology, immunology, neuroscience, and infectious diseases to patients in China and around the world.
Hua Medicine
(HK:02552)
drug development and commercialization company based in Shanghai, China. Hua Medicine focused on developing novel therapies for patients worldwide with unmet medical needs.
Henlius
(HK:2696)
a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases.
Rendu Biotechnology
(SH:688193)
focused on RNA detection technology innovation for 17 years, committed to providing more accurate and effective detection results and services for clinical use.
Sanyou Medical
(SH:688085)
a medical devices company specializing in the research, development, production, and sales of medical orthopedic implant consumables.
GemPharmatech
(SH:688046)
a leading contract research organization that provides genetically engineered mouse models and preclinical research services to the scientific community worldwide.
DreamCIS
(KOSDAQ:223250)
the largest CRO in Korea dedicated to provide clinical research services with over 1,200 successful projects to the pharmaceuticals, biotechnology, medical device and functional food industries.
Antegene Corporation
(HK:06996)
a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs.
InnoStar
(SH:688710)
support global pharmaceutical and biotech companies with drug discovery, ADME, PK/PD, toxicology, biomarkers, and bioanalysis services.
Structure
(NASDAQ:GPCR)
a clinical-stage biopharmaceutical company leveraging structure-based drug design to develop more accessible oral small molecule therapeutics for the treatment of chronic diseases including obesity and related diseases.
Abbisko
(HK:02256)
a R&D-driven, clinical-stage biopharmaceutical company dedicated to the discover and development of innnovative and differentiated small molecule oncology therapies.
Asieris
(SH:688176)
a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases.
PharmaResources
(SZ:301230)
a comprehensive one-stop service provider for new drug R&D as well as commercial production. We are dedicated to the drug discovery,pharmaceutical processes R&D, and the commercial manufacturing of APIs and intermediates.
Canbridge
(HK:01228)
a global biopharmaceutical company leveraging its foundation in China to develop and deliver life-changing therapeutics for rare diseases and rare oncology worldwide.
Genor Biopharma
(HK:06998)
an innovation-driven biopharma company with a pipeline of therapies covering the world's most prevalent cancer types (breast, lung, and gastrointestinal cancer) and hematological malignancies.
Smo Clinplus
(SZ:301257)
provides site management services to both local and global companies in research development in pharmaceuticals, medical devices, and health-related products.
FrontageLab
(HK:01521)
a global pharmaceutical development organization advancing drug discovery and development through integrated laboratory and clinical services.
HighTide
(HK:02511)
a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat patients with chronic metabolic diseases.
PegBio
(HK: 02565)
a biotechnology company focused on the in-house discovery and development of innovative therapies for chronic diseases with a particular emphasis on metabolic disorders.
GenFleet Therapeutics
(HK: 02595)
is dedicated to serving significant unmet medical needs globally in oncology and immunology.